Effectiveness of Canadian travel restrictions in reducing burden of SARS-CoV-2 variants of concern

Angela McLaughlin, Vincent Montoya, Rachel L. Miller, Canadian COVID-19 Genomics Network (CanCOGeN) Consortium, Michael Worobey, Jeffrey B. Joy
doi: https://doi.org/10.1101/2023.09.12.23294140

Article Information

doi 
https://doi.org/10.1101/2023.09.12.23294140
History 
  • September 14, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Angela McLaughlin1,2,
  2. Vincent Montoya1,
  3. Rachel L. Miller1,
  4. Canadian COVID-19 Genomics Network (CanCOGeN) Consortium,
  5. Michael Worobey3 and
  6. Jeffrey B. Joy1,2,4,*
  1. 1British Columbia Centre for Excellence in HIV/AIDS; British Columbia, V6Z 1Y6, Canada
  2. 2Bioinformatics, University of British Columbia; British Columbia, V5T 4S6, Canada
  3. 3Department of Ecology and Evolution, University of Arizona; Arizona, 85721, United States
  4. 4Department of Medicine, University of British Columbia; British Columbia, V5Z 1M9, Canada
  1. ↵*Corresponding author. Email: jjoy{at}bccfe.ca
Back to top
Posted September 14, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Effectiveness of Canadian travel restrictions in reducing burden of SARS-CoV-2 variants of concern
Angela McLaughlin, Vincent Montoya, Rachel L. Miller, Canadian COVID-19 Genomics Network (CanCOGeN) Consortium, Michael Worobey, Jeffrey B. Joy
medRxiv 2023.09.12.23294140; doi: https://doi.org/10.1101/2023.09.12.23294140
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area